Slpi, a protease inhibitor that has been shown to inhibit neutrophil infiltration but upregulated in carcinomas (34), was upregulated with ConA+Veh treatment when compared to the Naïve controls and reversed following TCDD treatment (Figure 7B). Here, SLPI is linked to carcinoma.